Literature DB >> 27295549

Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors.

T D Filippatos1, V Tsimihodimos1, M S Elisaf1.   

Abstract

Entities:  

Keywords:  Sodium-glucose co-transporter 2 inhibitors; arterial hypertension; blood pressure; body weight; uric acid

Year:  2016        PMID： 27295549     DOI： 10.1080/14656566.2016.1201073

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


× No keyword cloud information.
  9 in total

Review 1.  Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.

Authors:  Asadur Rahman; Hirofumi Hitomi; Akira Nishiyama
Journal:  Hypertens Res       Date:  2017-01-19       Impact factor: 3.872

2.  SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in Dahl SS rats.

Authors:  Olha Kravtsova; Ruslan Bohovyk; Vladislav Levchenko; Oleg Palygin; Christine A Klemens; Timo Rieg; Alexander Staruschenko
Journal:  Am J Physiol Renal Physiol       Date:  2022-04-25

Review 3.  Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).

Authors:  Charalampos I Liakos; Dimitrios P Papadopoulos; Elias A Sanidas; Maria I Markou; Erifili E Hatziagelaki; Charalampos A Grassos; Maria L Velliou; John D Barbetseas
Journal:  Am J Cardiovasc Drugs       Date:  2021-03       Impact factor: 3.571

4.  Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes.

Authors:  Ioanna Papakitsou; George Vougiouklakis; Moses S Elisaf; Theodosios D Filippatos
Journal:  Clin Pharmacol       Date:  2019-09-19

Review 5.  Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.

Authors:  Qingchun Zeng; Qing Zhou; Weitao Liu; Yutong Wang; Xingbo Xu; Dingli Xu
Journal:  Front Cardiovasc Med       Date:  2021-02-10

Review 6.  Crosstalk between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases.

Authors:  Al-Anood Al-Shamasi; Rozina Elkaffash; Meram Mohamed; Menatallah Rayan; Dhabya Al-Khater; Alain-Pierre Gadeau; Rashid Ahmed; Anwarul Hasan; Hussein Eldassouki; Huseyin Cagatay Yalcin; Muhammad Abdul-Ghani; Fatima Mraiche
Journal:  Int J Mol Sci       Date:  2021-11-24       Impact factor: 5.923

7.  Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.

Authors:  Charlotte C van Ruiten; Mark M Smits; Megan D Kok; Erik H Serné; Daniël H van Raalte; Mark H H Kramer; Max Nieuwdorp; Richard G IJzerman
Journal:  Cardiovasc Diabetol       Date:  2022-04-28       Impact factor: 8.949

8.  A Study on Methodologies of Drug Repositioning Using Biomedical Big Data: A Focus on Diabetes Mellitus.

Authors:  Suehyun Lee; Seongwoo Jeon; Hun-Sung Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2022-04-13

Review 9.  SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives.

Authors:  Alexia Piperidou; Charalampos Loutradis; Pantelis Sarafidis
Journal:  J Hum Hypertens       Date:  2020-08-10       Impact factor: 3.012
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.